Mobility Deficits Assessed With Mobile Technology: What Can We Learn From Brain Iron-Altered Animal Models?

Background: Recent developments in mobile technology have enabled the investigation of human movements and mobility under natural conditions, i.e., in the home environment. Iron accumulation in the basal ganglia is deleterious in Parkinson's disease (i.e., iron accumulation with lower striatal level of dopamine). The effect of iron chelation (i.e., re-deployment of iron) in Parkinson's disease patients is currently tested in a large investigator-initiated multicenter study. Conversely, restless legs syndrome (RLS) is associated with iron depletion and higher striatal level of dopamine. To determine from animal models which movement and mobility parameters might be associated with iron content modulation and the potential effect of therapeutic chelation inhuman. Methods: We recapitulated pathophysiological aspects of the association between iron, dopamine, and neuronal dysfunction and deterioration in the basal ganglia, and systematically searched PubMed to identify original articles reporting about quantitatively assessed mobility deficits in animal models of brain iron dyshomeostasis. Results: We found six original studies using murine and fly models fulfilling the inclusion criteria. Especially postural and trunk stability were altered in animal models with iron overload. Animal models with lowered basal ganglia iron suffered from alterations in physical activity, mobility, and sleep fragmentation. Conclusion: From preclinical investigations in the animal model, we can deduce that possibly also in humans with iron accumulation in the basal ganglia undergoing therapeutic chelation may primarily show changes in physical activity (such as daily “motor activity”), postural and trunk stability and sleep fragmentation. These changes can readily be monitored with currently available mobile technology.

[1]  Giancarlo Fortino,et al.  Body Sensor Network-Based Robust Gait Analysis: Toward Clinical and at Home Use , 2019, IEEE Sensors Journal.

[2]  Lee H. Schwamm,et al.  Teleneurology and mobile technologies: the future of neurological care , 2018, Nature Reviews Neurology.

[3]  O. Rascol,et al.  Iron as a therapeutic target for Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[4]  Walter Maetzler,et al.  Effect of Fear of Falling on Turning Performance in Parkinson’s Disease in the Lab and at Home , 2018, Front. Aging Neurosci..

[5]  D. Berg,et al.  The association between objectively measured physical activity, depression, cognition, and health-related quality of life in Parkinson's disease. , 2017, Parkinsonism & related disorders.

[6]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[7]  J. Rinne,et al.  Brain regional iron contents in progressive supranuclear palsy. , 2017, Parkinsonism & related disorders.

[8]  Samuel J. Reinfelder,et al.  Wearable sensors objectively measure gait parameters in Parkinson’s disease , 2017, PloS one.

[9]  Gert S. Faber,et al.  Validation of a Step Detection Algorithm during Straight Walking and Turning in Patients with Parkinson’s Disease and Older Adults Using an Inertial Measurement Unit at the Lower Back , 2017, Front. Neurol..

[10]  Tadeusz Sarna,et al.  Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease , 2017, Progress in Neurobiology.

[11]  Gert S. Faber,et al.  Algorithm for Turning Detection and Analysis Validated under Home-Like Conditions in Patients with Parkinson’s Disease and Older Adults using a 6 Degree-of-Freedom Inertial Measurement Unit at the Lower Back , 2017, Front. Neurol..

[12]  Lauren Gravitz,et al.  Technology: Monitoring gets personal , 2016, Nature.

[13]  Matthieu O. Pasquet,et al.  Wireless inertial measurement of head kinematics in freely-moving rats , 2016, Scientific Reports.

[14]  Ferdinand Schweser,et al.  Quantitative Susceptibility Mapping in Parkinson's Disease , 2016, PloS one.

[15]  Walter Maetzler,et al.  New methods for the assessment of Parkinson's disease (2005 to 2015): A systematic review , 2016, Movement disorders : official journal of the Movement Disorder Society.

[16]  Max A. Little,et al.  Technology in Parkinson's disease: Challenges and opportunities , 2016, Movement disorders : official journal of the Movement Disorder Society.

[17]  Alan Godfrey,et al.  Validation of an Accelerometer to Quantify a Comprehensive Battery of Gait Characteristics in Healthy Older Adults and Parkinson's Disease: Toward Clinical and at Home Use , 2016, IEEE Journal of Biomedical and Health Informatics.

[18]  Y. Ke,et al.  Differential interaction between iron and mutant alpha-synuclein causes distinctive Parkinsonian phenotypes in Drosophila. , 2016, Biochimica et biophysica acta.

[19]  Y Ben-Shlomo,et al.  Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial , 2016, The Lancet Neurology.

[20]  G. Halliday,et al.  Neuropathology of α‐synuclein propagation and braak hypothesis , 2016, Movement disorders : official journal of the Movement Disorder Society.

[21]  Jaap H. van Dieën,et al.  Physical Performance and Physical Activity in Older Adults: Associated but Separate Domains of Physical Function in Old Age , 2015, PloS one.

[22]  M. Giorgio,et al.  A novel neuroferritinopathy mouse model (FTL 498InsTC) shows progressive brain iron dysregulation, morphological signs of early neurodegeneration and motor coordination deficits , 2015, Neurobiology of Disease.

[23]  Athanassios G. Siapas,et al.  Structured Variability in Purkinje Cell Activity during Locomotion , 2015, Neuron.

[24]  P. Yu,et al.  Brain iron accumulation exacerbates the pathogenesis of MPTP-induced Parkinson’s disease , 2015, Neuroscience.

[25]  R. Allen,et al.  Low brain iron effects and reversibility on striatal dopamine dynamics , 2014, Experimental Neurology.

[26]  A. Walters,et al.  Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance. , 2014, Sleep medicine.

[27]  Blaine R. Roberts,et al.  An iron–dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta , 2014 .

[28]  Sebastiaan Overeem,et al.  Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[29]  J. Winkelmann,et al.  Restless legs syndrome: update on pathogenesis , 2013, Current opinion in pulmonary medicine.

[30]  B. Bloem,et al.  Quantitative wearable sensors for objective assessment of Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[31]  Alan Godfrey,et al.  Ambulatory activity in incident Parkinson’s: more than meets the eye? , 2013, Journal of Neurology.

[32]  N. Lindquist,et al.  Melanin affinity and its possible role in neurodegeneration , 2013, Journal of Neural Transmission.

[33]  R. Allen,et al.  The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia , 2013, American journal of hematology.

[34]  T. van Groen,et al.  Motor restlessness, sleep disturbances, thermal sensory alterations and elevated serum iron levels in Btbd9 mutant mice. , 2012, Human molecular genetics.

[35]  Christian Haass,et al.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences , 2012, The EMBO journal.

[36]  H. Jinnah,et al.  Sleep Fragmentation and Motor Restlessness in a Drosophila Model of Restless Legs Syndrome , 2012, Current Biology.

[37]  J. Li,et al.  Neuromelanin enhances the toxicity of α-synuclein in SK-N-SH cells , 2011, Journal of Neural Transmission.

[38]  P. Chan,et al.  Increase expression of α-synuclein in aged human brain associated with neuromelanin accumulation , 2011, Journal of Neural Transmission.

[39]  J. Connor,et al.  Profile of altered brain iron acquisition in restless legs syndrome. , 2011, Brain : a journal of neurology.

[40]  W. Paulus,et al.  Restless legs syndrome: pathophysiology, clinical presentation and management , 2010, Nature Reviews Neurology.

[41]  J. Connor,et al.  Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. , 2009, Brain : a journal of neurology.

[42]  J. Hedner,et al.  A randomized, double‐blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome , 2009, Movement disorders : official journal of the Movement Disorder Society.

[43]  P. Barker,et al.  A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. , 2009, Sleep medicine.

[44]  P. Cloetens,et al.  Intracellular chemical imaging of the developmental phases of human neuromelanin using synchrotron X-ray microspectroscopy. , 2008, Analytical chemistry.

[45]  B. Ghetti,et al.  Expression of a Mutant Form of the Ferritin Light Chain Gene Induces Neurodegeneration and Iron Overload in Transgenic Mice , 2008, The Journal of Neuroscience.

[46]  W. Paulus,et al.  Pathophysiological concepts of restless legs syndrome , 2007, Movement disorders : official journal of the Movement Disorder Society.

[47]  Kamiar Aminian,et al.  Quantification of Tremor and Bradykinesia in Parkinson's Disease Using a Novel Ambulatory Monitoring System , 2007, IEEE Transactions on Biomedical Engineering.

[48]  Kay L. Double,et al.  α-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease , 2005 .

[49]  D. Berg,et al.  In vivo detection of iron and neuromelanin by transcranial sonography: A new approach for early detection of substantia nigra damage , 2005, Movement disorders : official journal of the Movement Disorder Society.

[50]  M. Mattson,et al.  Role of dietary iron restriction in a mouse model of Parkinson's disease , 2004, Experimental Neurology.

[51]  J. Montplaisir,et al.  Circadian rhythm of restless legs syndrome: Relationship with biological markers , 2004, Annals of neurology.

[52]  N. Kıylıoğlu,et al.  Iron deficiency anemia and restless legs syndrome: is there an electrophysiological abnormality? , 2003, Clinical Neurology and Neurosurgery.

[53]  E. Hirsch,et al.  Neuromelanin associated redox‐active iron is increased in the substantia nigra of patients with Parkinson's disease , 2003, Journal of neurochemistry.

[54]  J. Connor,et al.  Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome , 2003, Neurology.

[55]  P. Riederer,et al.  Iron-binding characteristics of neuromelanin of the human substantia nigra. , 2003, Biochemical pharmacology.

[56]  Klaus W. Lange,et al.  Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson’s disease , 2003, NeuroImage.

[57]  M. Mattson,et al.  p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism , 2002, Annals of neurology.

[58]  Daniela Berg,et al.  Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. , 2002, Archives of neurology.

[59]  D. Berg,et al.  Brain iron pathways and their relevance to Parkinson's disease , 2001 .

[60]  John Hardy,et al.  The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity , 2000, The Journal of Neuroscience.

[61]  Luis Granero,et al.  Neurotoxic relationship between dopamine and iron in the striatal dopaminergic nerve terminals , 2000, Brain Research.

[62]  J. Crawley Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests 1 Published on the World Wide Web on 2 December 1998. 1 , 1999, Brain Research.

[63]  G Becker,et al.  Iron accumulation in the substantia nigra in rats visualized by ultrasound. , 1999, Ultrasound in medicine & biology.

[64]  H. Zoghbi,et al.  Purkinje Cell Expression of a Mutant Allele of SCA1in Transgenic Mice Leads to Disparate Effects on Motor Behaviors, Followed by a Progressive Cerebellar Dysfunction and Histological Alterations , 1997, The Journal of Neuroscience.

[65]  P. Ryvlin,et al.  Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. , 1995, Archives of neurology.

[66]  C D Marsden,et al.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.

[67]  D. Ben-shachar,et al.  The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons , 1991, Journal of neurochemistry.

[68]  P Riederer,et al.  Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains , 1991, Journal of neurochemistry.

[69]  Carlo Alberto Artusi,et al.  Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases. , 2018, Parkinsonism & related disorders.

[70]  Wiebren Zijlstra,et al.  Chair Rise Peak Power in Daily Life Measured With a Pendant Sensor Associates With Mobility, Limitation in Activities, and Frailty in Old People , 2017, IEEE Journal of Biomedical and Health Informatics.

[71]  James Robert Brašić,et al.  Increased synaptic dopamine in the putamen in restless legs syndrome. , 2013, Sleep.

[72]  W. Ondo,et al.  Projections of diencephalic dopamine neurons into the spinal cord in mice , 2005, Experimental Brain Research.